New research trials have shown considerable excitement regarding gantenerumab, a monoclonal antibody designed to remove amyloid deposits from the mind. Despite earlier attempts at amyloid-specific therapies have encountered challenges, gantenerumab's novel action and encouraging preliminary results suggest it may offer a greater opportunity of alte